CD274 and cancer: Synergy between immune checkpoint targeting and exosome depletion using GW4869 has been demonstrated in anti-tumor therapy (Wang J. S. et al., 2025), but cardiotoxicity has been associated to PD-L1 inhibitors in cancer patients (Liu et al., 2022).